Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00904
|
|||||
| Drug Name |
Adenosine
|
|||||
| Synonyms |
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Adenosine, homopolymer; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Anxiety [ICD11: MB24.3] | Approved | [1] | |||
| Therapeutic Class |
Antiarrhythmic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H13N5O4
|
|||||
| Canonical SMILES |
C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
|
|||||
| InChI |
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
|
|||||
| InChIKey |
OIRDTQYFTABQOQ-KQYNXXCUSA-N
|
|||||
| CAS Number |
CAS 58-61-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 267.24 | Topological Polar Surface Area | 140 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-1.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:16335
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ENT1 | Transporter Info | Equilibrative nucleoside transporter 1 | Substrate | [2] | |
| MRP5 | Transporter Info | Multidrug resistance-associated protein 5 | Substrate | [3] | ||
| References | ||||||
| 1 | Adenosine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60. | |||||
| 3 | Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.